|
Nov 05, 2019
|
Oyster Point Pharma Announces Closing of Initial Public Offering
PRINCETON, N.J., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, announced the closing of its initial
|
|
|
Oct 30, 2019
|
Oyster Point Pharma Announces Pricing of Initial Public Offering
PRINCETON, N.J., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced the pricing of its
|
|
|
Oct 04, 2019
|
Oyster Point Pharma Announces Filing of Registration Statement for Proposed Initial Public Offering
PRINCETON, N.J.--( BUSINESS WIRE )--Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that it has filed a registration
|
|
|
Sep 19, 2019
|
Oyster Point Pharma Expands Executive Leadership Team
Appoints Dan Lochner as Chief Financial Officer Appoints John Snisarenko as Chief Commercial Officer PRINCETON, N.J.--( BUSINESS WIRE )--Oyster Point Pharma, Inc., today announced the appointment of Dan Lochner, MBA as its Chief Financial Officer and John Snisarenko, MBA as Chief Commercial
|
|
|
Jul 24, 2019
|
Oyster Point Pharma Announces Enrollment of First Subject in Phase 3 Clinical Trial of Nasal Spray for Dry Eye Disease
PRINCETON, N.J. – July 24, 2019 – Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced enrollment of the first subject in the
|
|
|
Apr 25, 2019
|
Oyster Point Pharma to Present at the 2019 ASCRS•ASOA Annual Meeting and at the Ophthalmology Innovation Summit (OIS) Meeting
PRINCETON, New Jersey – April 25, 2019 – Oyster Point Pharma, Inc., a privately held clinical-stage pharmaceutical company with an initial focus on developing novel therapies for the treatment of Dry Eye Disease (DED), today announced multiple data presentations of the company’s product candidates
|
|
|
Mar 05, 2019
|
Oyster Point Pharma to Present at the Cowen and Company 39th Annual Health Care Conference
PRINCETON, New Jersey – March 5, 2019 – Oyster Point Pharma, Inc., a privately held clinical-stage pharmaceutical company with an initial focus on developing novel therapies for the treatment of Dry Eye Disease, today announced that Jeffrey Nau, Ph.D., M.M.S., President and CEO, is scheduled to
|
|
|
Feb 26, 2019
|
Oyster Point Raises $93 Million to Support the Clinical Development of Novel Treatment for Dry Eye Disease — Lead Clinical Candidate to Advance to Phase 3 Clinical Development
PRINCETON, N.J. – February 26, 2019 – Oyster Point Pharma, Inc., a privately held clinical-stage pharmaceutical company with an initial focus on developing novel therapies to treat Dry Eye Disease, today announced a $93 million Series B financing. The round was co-led by Invus Opportunities and
|
|
|
Feb 21, 2019
|
Oyster Point Pharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference
PRINCETON, New Jersey – February 21, 2019 – Oyster Point Pharma, Inc., a privately held clinical-stage pharmaceutical company with an initial focus on developing novel therapies for the treatment of Dry Eye Disease, today announced that Jeffrey Nau, Ph.D., M.M.S, President and CEO, is scheduled to
|
|
|
Jan 24, 2019
|
Oyster Point Pharma to Present at the BIO CEO & Investor Conference
PRINCETON, New Jersey – January 24, 2019 – Oyster Point Pharma, Inc., a privately held clinical-stage pharmaceutical company with an initial focus on developing novel therapies for the treatment of Dry Eye Disease, today announced that Jeffrey Nau, M.M.S., Ph.D., President and CEO, is scheduled to
|
|
